Centessa Pharmaceuticals (CNTA) Debt to Equity: 2022-2025
Historic Debt to Equity for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $0.36.
- Centessa Pharmaceuticals' Debt to Equity rose 140.10% to $0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.36, marking a year-over-year increase of 140.10%. This contributed to the annual value of $0.27 for FY2024, which is 15.33% down from last year.
- Centessa Pharmaceuticals' Debt to Equity amounted to $0.36 in Q3 2025, which was up 14.66% from $0.32 recorded in Q2 2025.
- Centessa Pharmaceuticals' Debt to Equity's 5-year high stood at $0.36 during Q3 2025, with a 5-year trough of $0.15 in Q3 2024.
- Over the past 3 years, Centessa Pharmaceuticals' median Debt to Equity value was $0.28 (recorded in 2025), while the average stood at $0.28.
- As far as peak fluctuations go, Centessa Pharmaceuticals' Debt to Equity plummeted by 46.84% in 2024, and later soared by 140.10% in 2025.
- Over the past 4 years, Centessa Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.21 in 2022, then spiked by 54.33% to $0.32 in 2023, then fell by 15.33% to $0.27 in 2024, then surged by 140.10% to $0.36 in 2025.
- Its Debt to Equity was $0.36 in Q3 2025, compared to $0.32 in Q2 2025 and $0.28 in Q1 2025.